The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
November 14, 2022
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
November 14, 2022 (Issue: 1663)
The FDA recently approved axicabtagene ciloleucel
(Yescarta – Kite), a CD19-directed genetically
modified cellular product, for treatment of large B-cell
lymphoma that is refractory to first-line chemoimmunotherapy
or that relapses within 12...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.